156 Les biomarqueurs moléculaires en oncologie
6. Mouliere F, Thierry AR (2012) The importance of examining the proportion of circulating
DNA originating from tumor, microenvironment and normal cells in colorectal cancer
patients. Expert Opin Biol Ther 2012(12): 18
7. Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or
serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat
Res 635(2-3): 105-17
8. Ramirez JL, Taron M, Balana C, et al. (2003) Serum DNA as a tool for cancer patient
l l
management. Rocz Akad Med Bialymst 48: 34-41
9. Madic J, Piperno-Neumann S, Servois V, et al. (2013) Pyrophosphorolysis-activated
polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer
Res 18(14): 3934-41
10. Kirk R (2013) Breast cancer: Circulating tumour DNA the better of the blood biomarkers.
Nat Rev Clin Oncol 10(5): 26
11. Benesova L, Belsanova B, Suchanek S, et al. (2013) Mutation-based detection and
l l
monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem
433(2): 227-34
12. Tong YK, Lo YM (2006) Diagnostic developments involving cell-free (circulating) nucleic
acids. Clin Chim Acta 363(1-2):187-96
13. Dawson SJ, Tsui DW, Murtaza M, et al. (2013) Analysis of circulating tumor DNA to
l l
monitor metastatic breast cancer. N Engl J Med 368(13): 1199-209
14. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring
cancer-genetics in the blood. Nat Rev Clin Oncol 10(8): 472-84
15. De Mattos-Arruda L, Cortes J, Santarpia L, et al. (2013) Circulating tumour cells and celll l
free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10(7): 377-89
16. Richardson AL, Iglehart JD (2012) BEAMing up personalized medicine: mutation
detection in blood. Clin Cancer Res 18(12): 3209-11
17. Murtaza M, Dawson SJ, Tsui DW, et al. (2013) Non-invasive analysis of acquired resistance
l l
to cancer therapy by sequencing of plasma DNA. Nature 497(7447): 108-12
18. El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA:
Preanalytical considerations. Clin Chim Acta 424: 222-30
19. Lauring J, Park BH (2011) BEAMing sheds light on drug resistance. Clin Cancer Res
17(24): 7508-10
20. Heitzer E, Auer M, Hoffmann EM, et al. (2013) Establishment of tumor-specific copy
l l
number alterations from plasma DNA of patients with cancer. Int J Cancer 133(2): 346-56
21. Higgins MJ, Jelovac D, Barnathan E, et al. (2012) Detection of tumor PIK3CA status in
l l
metastatic breast cancer using peripheral blood. Clin Cancer Res 18(12): 3462-9
22. Pohl G, Shih Ie M (2004) Principle and applications of digital PCR. Expert Rev Mol
Diagn 4(1): 41-7
23. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci U S A 96(16): 9236-41
24. Sanders R, Huggett JF, Bushell CA, et al. (2011) Evaluation of digital PCR for absolute
l l
DNA quantification. Anal Chem 83(17): 6474-84
25. Hindson BJ, Ness KD, Masquelier DA, et al. (2011) High-throughput droplet digital PCR
l l
system for absolute quantitation of DNA copy number. Anal Chem 83(22): 8604-10
26. Pinheiro LB, Coleman VA, Hindson CM, et al. (2011) Evaluation of a droplet digital
l l
polymerase chain reaction format for DNA copy number quantification. Anal Chem
84(2): 1003-11
27. Shuga J, Zeng Y, Novak R, et al. (2013) Single molecule quantitation and sequencing of
l l
rare translocations using microfluidic nested digital PCR. Nucleic Acids Res 41(16):e159
28. Pekin D, Skhiri Y, Baret JC, et al. (2011) Quantitative and sensitive detection of rare
l l
mutations using droplet-based microfluidics. Lab Chip 11(13): 2156-66
29. Brouzes E, Medkova M, Savenelli N, et al. (2009) Droplet microfluidic technology for
l l
single-cell high-throughput screening. Proc Natl Acad Sci USA 106(34): 14195-200
6. Mouliere F, Thierry AR (2012) The importance of examining the proportion of circulating
DNA originating from tumor, microenvironment and normal cells in colorectal cancer
patients. Expert Opin Biol Ther 2012(12): 18
7. Gormally E, Caboux E, Vineis P, Hainaut P (2007) Circulating free DNA in plasma or
serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat
Res 635(2-3): 105-17
8. Ramirez JL, Taron M, Balana C, et al. (2003) Serum DNA as a tool for cancer patient
l l
management. Rocz Akad Med Bialymst 48: 34-41
9. Madic J, Piperno-Neumann S, Servois V, et al. (2013) Pyrophosphorolysis-activated
polymerization detects circulating tumor DNA in metastatic uveal melanoma. Clin Cancer
Res 18(14): 3934-41
10. Kirk R (2013) Breast cancer: Circulating tumour DNA the better of the blood biomarkers.
Nat Rev Clin Oncol 10(5): 26
11. Benesova L, Belsanova B, Suchanek S, et al. (2013) Mutation-based detection and
l l
monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem
433(2): 227-34
12. Tong YK, Lo YM (2006) Diagnostic developments involving cell-free (circulating) nucleic
acids. Clin Chim Acta 363(1-2):187-96
13. Dawson SJ, Tsui DW, Murtaza M, et al. (2013) Analysis of circulating tumor DNA to
l l
monitor metastatic breast cancer. N Engl J Med 368(13): 1199-209
14. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A (2013) Liquid biopsy: monitoring
cancer-genetics in the blood. Nat Rev Clin Oncol 10(8): 472-84
15. De Mattos-Arruda L, Cortes J, Santarpia L, et al. (2013) Circulating tumour cells and celll l
free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 10(7): 377-89
16. Richardson AL, Iglehart JD (2012) BEAMing up personalized medicine: mutation
detection in blood. Clin Cancer Res 18(12): 3209-11
17. Murtaza M, Dawson SJ, Tsui DW, et al. (2013) Non-invasive analysis of acquired resistance
l l
to cancer therapy by sequencing of plasma DNA. Nature 497(7447): 108-12
18. El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA:
Preanalytical considerations. Clin Chim Acta 424: 222-30
19. Lauring J, Park BH (2011) BEAMing sheds light on drug resistance. Clin Cancer Res
17(24): 7508-10
20. Heitzer E, Auer M, Hoffmann EM, et al. (2013) Establishment of tumor-specific copy
l l
number alterations from plasma DNA of patients with cancer. Int J Cancer 133(2): 346-56
21. Higgins MJ, Jelovac D, Barnathan E, et al. (2012) Detection of tumor PIK3CA status in
l l
metastatic breast cancer using peripheral blood. Clin Cancer Res 18(12): 3462-9
22. Pohl G, Shih Ie M (2004) Principle and applications of digital PCR. Expert Rev Mol
Diagn 4(1): 41-7
23. Vogelstein B, Kinzler KW (1999) Digital PCR. Proc Natl Acad Sci U S A 96(16): 9236-41
24. Sanders R, Huggett JF, Bushell CA, et al. (2011) Evaluation of digital PCR for absolute
l l
DNA quantification. Anal Chem 83(17): 6474-84
25. Hindson BJ, Ness KD, Masquelier DA, et al. (2011) High-throughput droplet digital PCR
l l
system for absolute quantitation of DNA copy number. Anal Chem 83(22): 8604-10
26. Pinheiro LB, Coleman VA, Hindson CM, et al. (2011) Evaluation of a droplet digital
l l
polymerase chain reaction format for DNA copy number quantification. Anal Chem
84(2): 1003-11
27. Shuga J, Zeng Y, Novak R, et al. (2013) Single molecule quantitation and sequencing of
l l
rare translocations using microfluidic nested digital PCR. Nucleic Acids Res 41(16):e159
28. Pekin D, Skhiri Y, Baret JC, et al. (2011) Quantitative and sensitive detection of rare
l l
mutations using droplet-based microfluidics. Lab Chip 11(13): 2156-66
29. Brouzes E, Medkova M, Savenelli N, et al. (2009) Droplet microfluidic technology for
l l
single-cell high-throughput screening. Proc Natl Acad Sci USA 106(34): 14195-200